PCM
INO icon

Penserra Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Penserra Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-401
Closed -$34K – 1444
2021
Q3 		$34K Buy
401
+4
+1% +$401 ﹤0.01% 1156
2021
Q2 		$44K Buy
397
+7
+2% +$672 ﹤0.01% 1034
2021
Q1 		$43K Buy
390
+61
+19% +$8.02K ﹤0.01% 835
2020
Q4 		$34K Buy
329
+210
+176% +$28K ﹤0.01% 750
2020
Q3 		$16K Buy
+119
New +$24.8K ﹤0.01% 764

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Penserra Capital Management's INO Position: Q4 2021 in Review

Penserra Capital Management sold out of Inovio Pharmaceuticals (INO) in Q4 2021, closing a stake of 401 shares — an estimated $34K sold.

Penserra Capital Management first reported a position in INO in Q3 2020 and held it in 5 quarters. The position peaked at $44K in Q2 2021. 208 funds tracked by Wall St. Rank hold INO as of Q4 2021.

  • Penserra Capital Management reported no remaining Inovio Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 401 Inovio Pharmaceuticals shares in Q4 2021, an estimated $34K.
  • Penserra Capital Management first reported a position in Inovio Pharmaceuticals in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Inovio Pharmaceuticals position peaked at $44K in Q2 2021.
  • 208 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.